Home/Pipeline/RGI-3100

RGI-3100

Type 1 Diabetes (autoimmune)

PreclinicalActive

Key Facts

Indication

Type 1 Diabetes (autoimmune)

Phase

Preclinical

Status

Active

Company

About REGiMMUNE

Treg‑focused biotech delivering novel immunotherapies for GvHD, autoimmunity and oncology.

View full company profile

Therapeutic Areas

Oncology Immunology